Zacks Investment Research on MSN
Moderna (MRNA) increases despite market slip: Here's what you need to know
Moderna (MRNA) closed at $40.60 in the latest trading session, marking a +2.52% move from the prior day. The stock's change ...
One of the new members is Adam Urato, a maternal-fetal medicine doctor based in Massachusetts who has long fought against the ...
7hOpinion
I was silenced for exposing Covid vaccine injuries in 2021... now the truth has finally come out
A Covid vaccine researcher claims she was silenced for years right before warning the public about the dangers to certain ...
Nitin Joshi, PhD, and Jingjing Gao, PhD, of the Department of Anesthesiology at Mass General Brigham, are the co-senior ...
The cells in living organisms are constantly making proteins. Ribosomes, the RNA-protein complexes that make other proteins, ...
Osteoarthritis is a highly prevalent joint disease that leads to cartilage breakdown, pain and disability, yet there are ...
Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...
At the 44 th Annual JP Morgan Healthcare Conference on Monday, Moderna Inc. (NASDAQ:MRNA) said that it expects to report ...
Nitin Joshi, PhD, and Jingjing Gao, PhD, of the Department of Anesthesiology at Mass General Brigham, are the co-senior authors of a paper published in Nature Nanotechnology, “A ...
The U.S. is facing its worst flu season in 25 years, according to the Centers for Disease Control and Prevention, which ...
Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
The independent journey of CureVac on public markets has concluded. The Nasdaq exchange has suspended trading of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback